Novo-Nordisk A/S D
D
NVO
47.255
USD
1.29
(2.80%)
Post Trading·47.180USD-0.075(-0.16%)
Volume
438,386
EPS
22
Div Yield
3.92
P/E
12
Market Cap
208,902,565,823
Arincen
Market Roundup: What Happened Yesterday and What Awaits Us Today (February 10)
Arincen
Market Roundup: What Happened Yesterday and What Awaits Us Today (February 4)
Arincen
Novo Nordisk Shares Soar as FDA Clears First Weight-Loss Pill
Arincen
Novo Nordisk Cuts 9,000 Jobs as Obesity Drug Battle Intensifies
Arincen
M
R
Europe’s Biggest Companies Fall Further Behind US Rivals
Title: Novo/Nordisk A/S
Sector: Healthcare
Industry: Drug Manufacturers - General
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.